Mitomicina Accord (Mitomycin)

Mitomycin is an antineoplastic antibiotic used in chemotherapy regimens for solid tumor malignancies.

• Bladder cancer: administered intravesically to reduce tumor recurrence after transurethral resection.
• Gastric cancer: combined with other agents to enhance tumor response in advanced disease.
• Breast cancer: incorporated into combination protocols for metastatic or refractory disease.

• Mitomycin is a bioreductive alkylating agent that undergoes enzymatic reduction within hypoxic tumor cells, generating a reactive aziridine that forms covalent cross‑links between DNA strands. These interstrand cross‑links block DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells. The cross‑linking interferes with the cell cycle, particularly the S phase, and triggers DNA damage response pathways that culminate in programmed cell death.

Mitomicina Accord may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
• Myelosuppression: decreased white blood cells, neutrophils, and platelets.
• Fatigue: persistent tiredness affecting daily activities.
• Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects

• Severe bone marrow suppression: can lead to life‑threatening infections or bleeding.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis may develop.
• Hemolytic‑uremic syndrome: rare but serious renal and hematologic complication.
• Severe allergic reaction: anaphylaxis or serum‑sickness‑like symptoms.

When using Mitomicina Accord, several safety measures should be observed.

• Dose adjustment: renal or hepatic impairment may require modification of the regimen.
• Monitor blood counts: regular complete blood count testing is essential to detect myelosuppression early.
• Avoid use in pregnancy: potential teratogenic effects make it contraindicated for pregnant patients.
• Assess pulmonary status: pre‑existing lung disease increases the risk of pulmonary toxicity.
• Maintain adequate hydration: sufficient fluid intake helps reduce renal toxicity.
• Store at ambient temperature: keep in the original container, protect from light and moisture.

Mitomicina Accord can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Concurrent use with other alkylating agents: additive bone‑marrow toxicity.
• Combination with high‑dose radiation therapy: increased risk of severe tissue damage.
• Strong CYP450 inducers: may reduce mitomycin efficacy.

Moderate Interactions (Monitor Closely)

• Co‑administration with nephrotoxic drugs: monitor renal function closely.
• Antifungal azoles (e.g., fluconazole): may affect mitomycin metabolism.
• Use of growth‑factor support (e.g., G‑CSF): can mask the extent of myelosuppression.